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1. Introduction
Histological evaluation of liver allograft biopsies is an integral part of the management of
liver transplant patients. From the time of donor hepatectomy onward, the allograft is sus‐
ceptible to multiple insults, including warm and cold ischemia, complications related to sur‐
gical anastomoses, acute cellular rejection, and recurrence of underlying liver disease. It is
often quite challenging to distinguish these various entities by their clinical presentation
alone. In these situations, evaluation of a liver biopsy is frequently necessary to confirm the
diagnosis, to stage recurrent fibrosis, or to monitor response to treatment.
2. Post-transplant liver biopsy techniques
Liver biopsies can be performed with various techniques, including a percutaneous ap‐
proach (with marking by percussion/palpation, marking by ultrasound (US), or under real-
time US or computed tomography (CT) guidance), a transjugular approach, or a surgical/
laparoscopic approach. Although percutaneous liver biopsies on non-transplant patients can
be done without the use of imaging, it is recommended that patients who have undergone
any abdominal surgery (including liver transplantation) undergo biopsies aided by the use
of US to avoid vascular or other structures [1]. While US marking followed by biopsy is suf‐
ficient in most post-transplant patients, in certain situations (such as split-liver recipients),
biopsy under real-time US or CT guidance is preferred to avoid encountering intervening
bowel loops. While specimens at least 1.5cm in length and containing at least 6-8 portal tri‐
ads are considered adequate for the diagnosis of chronic liver disease [2,3], some advocate a
minimum length of 2.0 cm and at least 11 complete portal tracts for accurate grading and
staging of liver disease [4].
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Percutaneous liver biopsy can be performed rapidly and safely in an outpatient setting with
the appropriate monitoring equipment and staff availability [5]. After discharge, patients are
typically instructed to avoid strenuous physical activity or driving for 24-48 hours, and are
asked to contact the clinical provider in the event of concerning symptoms. In our institu‐
tion, a review of over 3,000 liver biopsies (including liver transplant patients) demonstrated
that the majority of complications were discovered within the first hour after percutaneous
liver biopsy, and that shortening the recovery time to 1-2 hours did not impact the frequen‐
cy of complications [6].
Percutaneous liver biopsy can be performed with suction needles (such as Jamshidi needle
or Menghini needle), cutting needles (such as the Tru-Cut needle), or spring-loaded needle
“guns”. Specimens adequate for diagnosis, grading, and staging can usually be obtained by
all of the biopsy needles used in current practice.
In patients with severe/uncorrectable coagulopathy, thrombocytopenia (typically platelet
count < 50,000/mm3), large ascites, morbid obesity, or an inability to cooperate, a transjugu‐
lar liver biopsy (TJLB) is typically recommended [7]. In addition, TJLB is useful in patients
for whom wedged hepatic venous pressure gradient (HVPG) measurement would be clini‐
cally useful. Miraglia et al reported on the safety of TJLB in liver transplant patients, with
only one complication in 183 biopsies (0.5%) [8].
TJLB  is  typically  performed  with  the  use  of  automated  needle  systems,  such  as  the
Quick-Core needle and the Flexcore needle. It has been established that these automated
needle  systems  often  require  multiple  passes,  and  usually  collect  smaller  core  samples
than  those  obtained  by  percutaneous  liver  biopsy  [9].  Despite  this  fact,  specimens  ob‐
tained via TJLB are adequate for diagnosis,  staging, and grading liver disease in greater
than 90% of cases [10,11].
Surgical liver biopsies (either open liver biopsy or laparoscopic liver biopsy) are typically
performed when patients require a surgical procedure for another indication. In liver trans‐
plant patients, this often involves repair of postoperative hernias. Biopsies in this setting can
be performed with either automated needle systems or with a wedge resection, and the pro‐
cedure provides the advantage of direct visualization of the liver and the ability to immedi‐
ately diagnose and treat any bleeding which occurs.
3. Complications of liver biopsy
Although invasive, liver biopsy is a relative safe procedure, whether performed percutane‐
ously or via the transvenous route. In a review of over 60,000 non-transplant patients, death
within seven days directly related to liver biopsy occurred in 1 out of every 10,000 proce‐
dures, and all-cause mortality within seven days occurred in approximately 0.2% of patients
[12]. Serious complications were similarly rare, with pain occurring in 2% of patients, hemo‐
peritoneum occurring in 0.04%, and hemobilia occurring in 0.01% [12]. Similarly, studies of
allograft liver biopsies demonstrate a mortality rate of up to 0.2%, and a rate of major com‐
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plications between 0.2% and 1.8% [13]. While early studies suggested an increased risk of
post-biopsy sepsis in patients with Roux-en-Y choledochojejunostomy, subsequent studies
show that the risk is similar to patients with a duct-to-duct anastomosis [14].
4. Post-transplant liver enzyme abnormalities
Abnormalities in liver enzyme levels are often encountered in liver transplant patients, and
can represent hepatocellular injury (reflected by the transaminases), biliary injury [reflected
by alkaline phosphatase or gamma-glutamyl transferase (GGT)], or hepatic synthetic dys‐
function (reflected by the albumin or by coagulation abnormalities). While the use of serum
blood tests (such as viral or autoimmune serologies) and imaging techniques (such as ultra‐
sound with Doppler, angiography, and magnetic resonance cholangiography) can be useful
to determine the etiology of abnormal liver enzymes, liver biopsy is often necessary for a
definitive diagnosis.
5. Early post-transplant liver enzyme abnormalities
The differential diagnosis of liver enzyme abnormalities varies with the amount of time
which has passed since liver transplant. In the normal post-transplant course, liver enzymes
typically rise immediately following transplant and become normal or near-normal within
3-5 days. If the enzymes fail to improve or normalize but soon rise again, it is likely that an
early complication has occurred (Table 1). In the very early post-transplant period (within
the first week), liver enzyme abnormalities can be related to primary graft nonfunction
(PNF) or dysfunction, hepatic arterial insufficiency, small for size syndrome (SFSS), or portal
venous thrombosis (PVT).
5.1. Primary graft dysfunction
PNF and primary graft dysfunction are associated with prolonged ischemia time [15], and it
is likely that preservation and reperfusion injury play a role. PNF is heralded by a precipi‐
tous rise in hepatic transaminases in the second or third postoperative day accompanied by
signs of hepatic failure (encephalopathy and coagulopathy). Once hepatic artery thrombosis
(HAT) has been ruled out by imaging, a liver biopsy confirms the diagnosis. Biopsies in this
setting typically show centrilobular hepatocyte dropout due to hepatocellular necrosis, with
compensatory zone 2 hepatocyte proliferation and bile ductular proliferation [16].
5.2. Hepatic artery thrombosis
The clinical presentation of HAT is quite similar to that of PNF, with a dramatic increase in
hepatic transaminases and bilirubin in the very early post-transplant period. A liver biopsy
is typically not required, as the diagnosis can usually be confirmed with angiography. When
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performed, biopsies of patients with hepatic arterial insufficiency show hepatocyte foamy
degeneration or necrosis and features of ischemic cholangitis [17].
Disease/
Complication
Incidence Time of
presentation
Clinical presentation Risk Factors Histological
Characteristics
Preservation/
Reperfusion
Injury
Up to 30%
(2-7% severe)
[15]
Within 3 days Elevated transaminases,
bilirubin, INR.
Encephalopathy in
severe injury
Prolonged cold or warm
ischemia time, greater
than 30% donor steatosis
Centrilobular
hepatocyte
dropout, zone 2
hepatocyte
proliferation, bile
duct proliferation
[16]
Hepatic artery
thrombosis
3-10% in
adult
transplant (up
to 40% in
pediatric
transplant)
[17]
Day 2 to 7 post-
transplant
Severe elevation of
transaminases, bilirubin,
alkaline
phosphatase/GGT
Technical/anastomotic
complications
Foamy
hepatocyte
degeneration,
features of
ischemic
cholangitis
Acute Cellular
Rejection
24-80% by 6
months post-
transplant
[26]
Typically 2-3
weeks after
transplant, up to
3 months post-
transplant
Elevated transaminases,
bilirubin, alkaline
phosphatase. Possible
recent history of
inadequate
immunosuppression
Younger recipient, older
donor, history of
autoimmune disorder, ?
female recipient
[17]
Portal
inflammation,
biliary
inflammation,
endothelitis
Portal vein
thrombosis
Less than 1% Early: within first
week post-
transplant
Late: within first
year post-
transplant
Early: acute hepatic
failure
Late: ascites, variceal
bleeding
Hypercoagulable state,
prior history of PVT
Often normal,
may show
features of focal
nodular
hyperplasia [21,
22]
Small for size
syndrome
Not well
defined, but
greatest when
graft-to-
recipient body
weight ratio is
less than 0.6
[18]
Sequelae of
portal
hypertension: 6
to 12 months
post-transplant
Ascites, spontaneous
bacterial peritonitis,
variceal bleeding
Graft-to-recipient body
weight ratio less than 0.6
[18, 19]
Centrilobular
cholestasis and
steatosis,
interface bile duct
inflammation [20]
Table 1. Differential diagnosis of early post-transplant liver enzyme abnormalities
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5.3. Portal vein thrombosis
Early acute PVT presents clinically as acute hepatic failure and demonstrates histological
features of hepatocyte necrosis. Occasionally, PVT presents later, in which case the features
of portal hypertension dominate. In this situation, if a biopsy is performed, it can be normal
or show features of nodular regenerative hyperplasia [18,19].
5.4. Small for size syndrome
Patients with SFSS present with dominant features of portal hypertension, such as ascites
and variceal bleeding. This syndrome is the result of relative portal hyperperfusion com‐
pared to hepatic arterial blood flow, and often occurs when the transplanted liver (or liver
segment) is less than 0.6- 0.8% of the recipient body weight [20,21]. The diagnosis is typically
made clinically, with signs of portal hypertension such as ascites and variceal bleeding. If a
liver biopsy is performed, the allograft typically shows centrilobular cholestasis, centrilobu‐
lar steatosis, and interface ductular proliferation [22].
5.5. Acute cellular rejection
The most common cause of  early allograft  dysfunction is  acute cellular  rejection (ACR).
Although most cases of ACR occur in the first three months post-transplant (most often
in  the  second or  third  post-transplant  week),  late-onset  ACR (occurring  up to  10  years
post-transplant) has been reported [23]. ACR typically presents as moderate to severe el‐
evations  in  hepatic  transaminases  and  alkaline  phosphatase/GGT,  with  some  degree  of
bilirubin elevation, often in patients with a recent history of inadequate immunosuppres‐
sion. The “gold standard” for the diagnosis of ACR remains the liver biopsy, which typi‐
cally  shows  variable  degrees  of  mixed  portal  inflammation  (often  with  increased
eosinophils), bile duct inflammation, and endotheliitis (typically in the portal vein or cen‐
tral  vein  branches)  (Figure  1).  The  Banff  criteria  are  the  most  widely  used  to  describe
ACR,  and give  a  score  of  1-3  for  each  component.  These  scores  are  added to  calculate
the Rejection Activity Index (RAI), which ranges from 3-4 (mild ACR) up to greater than
7 (severe ACR) [24]. It should be noted that late-onset ACR often appears quite different
histologically, with a greater likelihood of lobular inflammation, less prominent bile duct
inflammation, and a tendency towards monotypic portal inflammation [25].  A follow-up
liver biopsy after 3-7 days of increased immunosuppression is occasionally used to con‐
firm response to treatment.
5.6. Late post-transplant liver enzyme abnormalities
Beyond three months post-transplant, the differential of liver enzyme abnormalities
changes. Broadly, the diagnoses can be categorized as chronic rejection, native disease recur‐
rence, de novo infectious complications, toxic complications, de novo hepatitis, or vascular
complications (Table 2).
Liver Biopsy After Liver Transplantation
http://dx.doi.org/10.5772/52617
193
Figure 1. Acute rejection, with endotheliitis (arrowhead), bile duct destruction (arrow), and mixed portal inflamma‐
tion (40x, H&E)
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Disease/
Complication
Incidence Time of
presentation
Clinical presentation Risk Factors Histological
Characteristics
Chronic rejection 3-5% 3-12 months after
transplant
Rising alkaline
phosphatase/GGT, late
elevation in bilirubin
Inadequate
immunosuppression, history
of multiple episodes of or
ongoing acute cellular
rejection [17]
Bile duct atrophy/loss,
foamy arteriopathy [26]
Recurrent HCV Near-universal Re-infection
within 72 hours;
histological
recurrence within
1-2 weeks;
clinically
significant
recurrence within
3 years (within 1
year for FCH) [27]
Elevated transaminases
in typical recurrent HCV
FCH: jaundice, marked
elevation of alkaline
phosphatase/GGT,
extremely high HCV viral
load
FCH: excessive
immunosuppression
Portal inflammation,
interface hepatitis, lobular
activity [28-30]
FCH: cholestasis, fibrosis
[35]
Recurrent HBV Less than 10%
with adequate
prophylaxis [36]
Typical recurrent
HBV: 6-12 months
post-transplant
FCH: within 1
month post-
transplant
Elevated transaminases,
elevated HBV viral load
Inadequate prophylaxis Lymphoplasmacytic portal
inflammation, Kupffer cell
hypertrophy, lobular
disarray; ground-glass
hepatocytes; positive
immunostaining for
hepatitis B surface antigen
and core antigen [37]
Recurrent AIH Up to 40% [38] Variable Slow progression of
transaminase elevation
Inadequate
immunosuppression, native
type II AIH
Lymphoplasmacytic portal
infiltrate, prominent
interface activity [29]
CMV infection 5-8% with
prophylaxis
1-12 months
post-transplant
CMV hepatitis: Elevated
transaminases
Extrahepatic CMV:
gastroenteritis, colitis,
pneumonitis
Graft from CMV-antibody-
positive donor into CMV-
antibody-negative recipient
Portal inflammation,
hepatocytes with CMV
inclusions, focal bile duct
damage [29]
EBV infection Up to 80% of
patients who are
EBV-antibody-
negative at time
of transplant
6-12 or more
months post-
transplant
EBV hepatitis: usually
asymptomatic
PTLD: lymphoma-like
presentation
Primary infection: EBV-
antibody-negative recipient
Progression to PTLD:
excessive
immunosuppression,
preceding CMV infection
[43]
EBV hepatitis: portal and
sinusoidal infiltrates with
atypical lymphocytes,
+EBER
PTLD: immunoblasts, with
varying degrees of
architectural distortion [45]
Table 2. Differential diagnosis of late post-transplant liver enzyme abnormalities
Liver Biopsy After Liver Transplantation
http://dx.doi.org/10.5772/52617
195
5.7. Chronic rejection
Chronic rejection involves immune-mediated injury to the hepatic arterial endothelium and
bile duct epithelium. It is most commonly seen in patients who have experienced repeated
bouts of significant ACR and/or have a recent history of inadequate immunosuppression.
The typical clinical presentation is a slow rise in alkaline phosphatase/GGT, often followed
by a rise in bilirubin. Procurement of an adequate biopsy sample (with at least ten complete
portal triads) is crucial in the histologic diagnosis of chronic rejection [26]. The minimal cri‐
teria for diagnosis of chronic rejection, as defined by the 2000 Banff recommendations, are
(1) bile duct atrophy/pyknosis affecting a majority of bile ducts (with or without bile duct
loss); (2) foam cell obliterative arteriopathy (Figure 2); or (3) bile duct loss in greater than
half of the portal tracts [26].
Figure 2. Foamy arteriopathy in the setting of chronic rejection (H&E 10x)
In the months and early years following liver transplant, recurrence of the underlying dis‐
ease which led to transplant becomes a common problem. Disease recurrence can be viral
(most commonly hepatitis B or C), immunological (such as autoimmune hepatitis, primary
sclerosing cholangitis [PSC], or primary biliary cirrhosis [PBC]), metabolic (such as non-alco‐
holic fatty liver disease [NAFLD]), malignant (hepatocellular carcinoma or cholangiocarci‐
noma), or idiopathic. The diagnosis of recurrent PSC, PBC, NAFLD, and malignancy is
relatively straightforward and is therefore not discussed further. However, the degree of
clinical and histological overlap between entities such as rejection, recurrent viral hepatitis,
and autoimmune hepatitis can create diagnostic conundrums without close clinicopatholog‐
ical correlation.
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5.8. Recurrent hepatitis C
Recurrent hepatitis C (HCV) infection is a universal phenomenon after liver transplantation,
and exhibits an accelerated progression to advanced liver disease [27]. Particularly in the
early months after transplant, the differential diagnosis of abnormal liver enzymes in HCV
patients includes both ACR and recurrent HCV. These entities are usually distinguished his‐
tologically. Histologically established recurrent HCV demonstrates portal inflammation, of‐
ten with lymphoid aggregates, interface hepatitis, and lobular disarray [28-30] (Figure 3).
There is often a component of ductular reaction, which is uncommon in HCV in native liv‐
ers [30]. While endotheliitis was traditionally considered specific to rejection, recent data
demonstrate portal branch endothelitis in biopsies of native HCV livers [31,32]. It does ap‐
pear that moderate to severe central vein branch endotheliitis remains fairly specific for re‐
jection. In a prospective analysis of biopsies from 48 HCV transplant patients, Demetris et al
described strict criteria to avoid overdiagnosis of ACR: (1) inflammatory bile duct injury in
at least 50% of portal tracts, and/or (2) mononuclear perivenular inflammation with hepato‐
cyte necrosis in at least 50% of terminal hepatic venules [33]. In cases where the differentia‐
tion of ACR and recurrent HCV is not clear, the use of an immune function assay can be a
useful adjunct [34]. Occasionally, recurrent HCV presents aggressively, in an entity known
as fibrosing cholestatic hepatitis (FCH). The risk of FCH increases with aggressive immuno‐
suppression, such as that used to treat ACR. Histologically, FCH is distinguished by a prom‐
inent component of cholestasis and fibrosis [35].
Figure 3. Recurrent HCV, with chronic portal inflammation (ellipse), and interface as well as lobular activity (H&E,10x)
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5.9. Recurrent hepatitis B
Recurrent hepatitis B (HBV) infection was common in the era before combination prophy‐
laxis with hepatitis B immunoglobulin and oral antiviral agents. The current rate of recur‐
rent HBV (less than 10%) is attributed to a lack of prophylaxis for various reasons [36].
Histologically, recurrent HBV demonstrates lymphoplasmacytic portal inflammation,
Kupffer cell hypertrophy, and lobular disarray [37]. Ground glass cells containing HBV sur‐
face antigen are often seen. Immunostaining demonstrates HBV surface antigen in hepato‐
cyte cytoplasm and HBV core antigen in hepatocyte nuclei. Recurrent HBV can also cause
FCH, characterized by cholestasis, perisinusoidal fibrosis, and swollen hepatocytes with im‐
munoreactivity for HBV core antigen [37]. In patients without demonstrable HBV core anti‐
gen staining, other causes of hepatic dysfunction should be sought.
5.10. Recurrent and de novo autoimmune hepatitis
Recurrence of autoimmune hepatitis (AIH) can occur in up to 40% of patients, but the course
is typically slowly progressive [38]. The biochemical/serological diagnosis of AIH [39] can be
difficult in post-transplant patients, and therefore a liver biopsy is often required for a defin‐
itive diagnosis. In the chronic phase, recurrent AIH demonstrates lymphoplasmacytic portal
infiltrate with prominent interface activity, perivenular activity and variable degrees of lob‐
ular necroinflammatory activity [29] (Figure 4). In patients without a pre-transplant history
of AIH, the findings of lymphoplasmacytic infiltrate and perivenular activity, the differen‐
tial diagnosis includes recurrent HCV, rejection, and de novo AIH. This distinction relies on
close clinicopathological correlation which takes into account the timing of onset, the immu‐
nosuppressive state, and the degree of perivenular damage [40].
Figure 4. Portal area with interface hepatitis, numerous plasma cells (arrowhead) and scattered eosinophils (arrow)
(H&E, 40x)
Liver Biopsy - Indications, Procedures, Results198
Liver transplant patients are also at risk of de novo infections due to their immunosup‐
pressed state. While the diagnosis of most of these infections is fairly straightforward, post-
transplant cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection can be more
difficult.
5.11. CMV infection
CMV is the most common clinically significant viral infection after solid organ transplanta‐
tion, with an incidence of up to 30% prior to the use of routine prophylaxis [41]. The risk of
post-transplant CMV infection is greatest in CMV-antibody-negative recipients who receive
a graft from a CMV-antibody-positive donor. Clinically, CMV infection can present with fe‐
ver, myelosuppression, and/or organ involvement (such as gastritis, colitis, hepatitis, or
pneumonitis). While detection of CMV in the serum can provide a rapid diagnosis, a liver
biopsy is often required to distinguish CMV from allograft rejection or demonstrate that
both entities are present [42]. Typically, CMV hepatitis is characterized by mononuclear or
mixed portal inflammation, focal bile duct damage, and hepatocytes with CMV inclusions
(large eosinophilic nuclear inclusions surrounded by a clear halo [29] (Figure 5). Although
some features similar to allograft rejection (portal lymphocytic inflammation, mild endothe‐
liitis) can be seen in CMV hepatitis, immunostaining for CMV antigens and/or the presence
of CMV inclusions confirms that CMV is the driving force behind the hepatic dysfunction.
Figure 5. Hepatocyte with intranuclear CMV inclusion (arrowhead) (H&E, 100x)
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5.12. EBV infection and post-transplant lymphoproliferative disorder
The clinical presentation of EBV infection can vary from asymptomatic hepatitis to post-
transplant lymphoproliferative disorder (PTLD). Patients without pre-transplant immunity
to EBV are at the greatest risk of infection. Patients with primary post-transplant EBV infec‐
tion, those with previous symptomatic CMV infection, and those with recent excessive im‐
munosuppression are at the highest risk for progression to PTLD [43]. EBV hepatitis
typically demonstrates portal and sinusoidal infiltrates consisting of atypical lymphocytes.
Often the lymphocytes are arranged in a single-file pattern within sinusoids [29]. Another
histological pattern which can be seen in EBV hepatitis consists of mixed periportal and si‐
nusoidal infiltrates with large atypical mononuclear cells and immunoblasts, mild bile duct
damage, and hepatic lobular activity [44]. The finding of EBV-encoded RNAs (EBERs) is
confirmatory in most cases.
PTLD is a heterogeneous lymphoproliferative disease divided into three main categories:
early lesions, polymorphic PTLD, and monomorphic PTLD [45]. Early lesions demonstrate
plasmacytic hyperplasia, and may or may not have prominent immunoblasts [29,45]. Poly‐
morphic PTLD is  characterized by mixed infiltrates of  monoclonal  or polyclonal  plasma
cells,  immunoblasts,  and  destruction  of  the  underlying  lymphoid  architecture  [45].  In
monomorphic  PTLD,  most  cases  arise  from B cell  populations  which demonstrate  inva‐
sion, architectural effacement, and cellular atypia [29]. A fourth category, Hodgkin’s lym‐
phoma-like PTLD, is sometimes described [46], and appears histologically like Hodgkin’s
lymphoma which occurs in non-transplant patients. PTLD patients with positive EBER re‐
sults  may represent relatively better  histopathological  features than patients with EBER-
negative PTLD [47].
6. Indication and protocol liver biopsies
The majority of post-transplant liver biopsies are performed in response to changes in liver
enzyme levels and/or abnormal imaging findings. Particularly in the early post-transplant
period, these so-called “indication” biopsies are usually diagnostic and often result in a
change in management. However, as patient and graft survival continues to improve, it has
become clear that normal histology is rarely seen in the long-term liver graft [48]. What is
not clear, however, is whether the histologic abnormalities seen in most late allograft biop‐
sies correlate to clinically-significant disease, and whether the routine use of so-called “pro‐
tocol” liver biopsies (performed at regular time points despite normal liver enzyme levels) is
clinically justified. In our institution, we no longer perform annual protocol biopsies on pa‐
tients with alcoholic liver disease, non-alcoholic fatty liver disease, or cryptogenic liver dis‐
ease. The use of annual or semi-annual protocol biopsies in patients with AIH, PSC, or PBC
is left to the discretion of the treating provider and/or the desires of the patient. In all HCV
patients, protocol biopsies are performed at four months post-transplant, at one year post-
transplant, and annually thereafter for at least the first five years. In contrast, an informal
survey of 35 transplant centers found that only 65% of centers perform protocol liver biop‐
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sies for HCV patients, and only 25% of centers perform protocol biopsies for other post-
transplant patients [13].
The rationale for protocol biopsies is the detection of those patients with severe dysfunction
in the hopes that early treatment and/or change in immunosuppression might improve graft
survival. However, the evidence of the clinical utility of these biopsies is conflicted. In stud‐
ies of long-term protocol biopsies in non-viral hepatitis transplant patients, it does appear
that histological abnormalities in the setting of normal liver enzymes likely are not clinically
significant [49,50]. The rationale for the use of protocol liver biopsies in HCV patients is the
identification of those with severe HCV recurrence in the hopes that prompt treatment
could improve graft survival [51]. This appears to be justified, as several studies have dem‐
onstrated the clinical utility of protocol biopsies in HCV patients, even as long as 20 years
post-transplant [52-54]. It is notable, however, that the vast majority of patients with recur‐
rent HCV (and all patients with severe recurrent HCV) had abnormal liver enzymes at the
pre-determined time of protocol biopsy.
A separate but equally important factor in long-term patient survival is the avoidance of ex‐
trahepatic complications of chronic immunosuppression, including renal insufficiency, the
development of diabetes mellitus, and infectious complications. In this regard, another utili‐
ty of protocol liver biopsy is the identification of those patients in whom immunosuppres‐
sion can be safely lowered. A retrospective study of patients with various liver diseases
found that protocol biopsy results led to a change in immunosuppression in almost on third
of patients [55]. Recently, an international working group developed recommendations for
protocol biopsy monitoring in patients in whom minimizing or weaning immunosuppres‐
sion is being considered [56].
7. Summary
The liver allograft is susceptible to a broad range of insult and injury from the time that it is
removed from the donor. While some complications are easily diagnosed by the clinical pre‐
sentation and advanced imaging, the majority of conditions display overlapping clinical fea‐
tures. As the treatment of these various conditions can be radically different, a definitive
diagnosis is crucial. To that end, post-transplant liver biopsy continues to play a key role in
the evaluation of liver transplant patients with hepatic dysfunction. While the role of proto‐
col biopsies in patients with no biochemical evidence of hepatic dysfunction has begun to
fall out of favor (especially in non-HCV patients), the use of biopsy in immunosuppression-
weaning protocols could promote a renewed interest in this methodology. The current data
support the use of protocol biopsies in HCV patients (particularly in the first few years post-
transplant). Areas for future investigation include non-invasive alternatives to liver biopsy
such as immune assays and advanced imaging, and the use of routine protocol biopsies in
weaning of immunosuppression.
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